Peer-influenced content. Sources you trust. No registration required. This is HCN.

Psych Congress NetworkStimulant Use May Increase Heart Damage Risk in Young Adults with ADHD

Evaluating Cardiovascular Risk in Young Adults on ADHD Stimulant Therapy

Recent findings from a comprehensive study published in the Journal of the American College of Cardiology highlight a subtle but significant risk of heart damage associated with prolonged stimulant medication use in young adults diagnosed with ADHD. This analysis explores the balance of therapeutic benefits against potential cardiovascular risks, paving the way for informed clinical decisions in managing ADHD with stimulant medications.

Key Points:

  • Study Basis and Demographics: The study analyzed a cohort of young adults aged 20-40 diagnosed with ADHD, utilizing the TriNetX database to compare heart health outcomes between those who used stimulant medications and those who did not.
  • Medication Duration and Cardiomyopathy Incidence: Data revealed a correlation between the duration of stimulant medication use and the incidence of cardiomyopathy. Notably, the risk increases with longer medication use, peaking at eight years.
  • Risk Quantification: Patients on stimulants for 10 years exhibited a cardiomyopathy prevalence of 0.72%, compared to 0.53% in their non-stimulant-using counterparts. The odds of developing cardiomyopathy were 1.57 times higher at eight years of usage.
  • Clinical Implications: The study stresses the importance of monitoring cardiovascular health in patients undergoing long-term stimulant therapy for ADHD, suggesting the need for periodic evaluation to mitigate potential risks.
  • Author Commentary: The lead author, Pauline Gerard, emphasized the significance of these findings in the context of prescribing practices, advocating for awareness and consideration of cardiovascular risks when choosing long-term ADHD treatments.

“The longer you leave patients on these medications, the more likely they are to develop cardiomyopathy, but the risk of that is very low. I don’t think this is a reason to stop prescribing these medications. There’s very little increased risk of these medications over the long term; it’s a real risk, but it’s small.”
– Pauline Gerard, Lead Author and second-year medical student at the University of Colorado School of Medicine in Aurora, Colorado

More on Drug Safety & Interactions

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form